{"id":"W3088957710","doi":"10.1016/j.annonc.2020.08.376","title":"274O Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AbbVie","keywords":"Medicine; Veliparib; Internal medicine; Breast cancer; Carboplatin; Brief Pain Inventory; Quality of life (healthcare); Oncology; Cancer; Metastatic breast cancer; Placebo; Hazard ratio; PARP inhibitor; Adverse effect; Paclitaxel; Physical therapy; Chemotherapy; Poly ADP ribose polymerase; Confidence interval; Chronic pain; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008414204,0.0004621915,0.0009653281,0.0001256261,0.0002743163,0.0007432402,0.0003079582,0.0004009672,0.00219191],"category_scores_gemma":[0.0004653548,0.0001958615,0.001608174,0.0003818832,0.0002194119,0.0002985123,0.0002548144,0.001281392,0.0003338563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005084256,"about_ca_system_score_gemma":0.0005101821,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00125561,"about_ca_topic_score_gemma":0.002568755,"domain_scores_codex":[0.9996964,0.0001389097,0.00001649292,0.00004225575,0.00003394988,0.00007203509],"domain_scores_gemma":[0.9997818,0.0000450768,0.00006613757,0.00001849674,0.00001929545,0.00006924102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7503936,0.009653435,0.1363078,0.0007945983,0.006343859,0.0002010468,0.0001140531,0.002591683,0.01310982,0.000230098,0.004498166,0.07576178],"study_design_scores_gemma":[0.2131924,0.1479527,0.6200013,0.0001333114,0.00485108,0.000289768,0.0001971448,0.002078994,0.004302149,0.0003398204,0.006589661,0.00007174437],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9941696,0.001869824,0.0001615264,0.0001608506,0.00004902954,0.0002208591,0.001786826,0.00001390013,0.001567542],"genre_scores_gemma":[0.9952843,0.0007496892,0.0002014771,0.0003024616,0.00004269985,0.0002182646,0.002250336,0.000004639785,0.0009460727],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00219191,"threshold_uncertainty_score":0.007332623,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1710767400481753,"score_gpt":0.4766115590990094,"score_spread":0.3055348190508341,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}